© 2015 Wichg Publishing
JVA
ISSN 1129-7298
J Vasc Access 2015; 16 (5): 377-381
ORIGINAL ARTICLE
with minimal complicaons. Tunneled permanent catheters
(TPCs) are being increasingly used for VA. These chronic in-
dwelling devices may be an unrecognized source of chronic
inflammaon in HD paents.
High sensive C-reacve protein (hs-CRP), the main acute
phase protein, and high hs-CRP levels indicate persistent in-
flammaon and predict overall mortality in CKD paents (4, 5).
Although there is a strong correlaon between increased hs-
CRP levels and TPC in HD paents (6-8), hs-CRP is not an ideal
marker to assess inflammatory reacons during HD because
of its delay in response to smuli and its large intra-individual
and inter-individual variability (9).
Pentraxin 3 (PTX3) is a recently discovered acute phase
protein. It is rapidly produced by different cell types, parcu-
larly mononuclear phagocytes, dendric cells, fibroblasts
and endothelial cells in response to proinflammatory signals
by smuli, including bacterial products, interleukin-1β and
tumor necrosis factor-α (TNF-α) (10-15). Prior studies have
demonstrated that PTX3 is a reliable and rapidly responsive
inflammatory marker (16, 17). PTX3 levels are elevated in
CKD and HD paents and increased PTX3 levels were asso-
ciated with increased mortality and cardiovascular disease
(18, 19).
DOI: 10.5301/jva.5000409
Relaonships between plasma pentraxin 3 levels
and inflammaon markers paents with tunneled
permanent catheter in hemodialysis
Irem Pembegul Yigit
1
, Ayhan Dogukan
2
, Hulya Taskapan
3
, Melda Comert
4
, Necip Ilhan
5
, Ramazan Ulu
2
, Bilge Aygen
2
1
Department of Nephrology, Malatya Government Hospital, Malatya - Turkey
2
Department of Nephrology, Faculty of Medicine, Firat University, Elazig - Turkey
3
Department of Nephrology, Faculty of Medicine, Inonu University, Malatya - Turkey
4
Department of Hematology, Faculty of Medicine, Ege University, Izmir - Turkey
5
Department of Biochemistry, Faculty of Medicine, Firat University, Elazig - Turkey
Introducon
Inflammaon increases with progression of chronic kid-
ney disease (CKD) and aſter the start of renal replacement
therapy, especially during hemodialysis (HD) (1). Chronic in-
flammaon contributes to malnutrion, atherosclerosis and
cardiovascular disease (2). Inflammaon in HD paents may
be related to vascular access (VA), genec factors, dialysate
quality, bioincompable membranes, comorbid condions,
decreased anoxidants, low solute clearance and increased
producon of proinflammatory cytokines (3). The goal of
chronic VA is to provide repeated access to the circulaon
ABSTRACT
Purpose: Vascular access (VA) devices may contribute to chronic inflammaon in hemodialysis (HD). Pentraxin 3
(PTX3) is a recently discovered acute phase protein that responds more rapidly than other inflammatory markers.
This study compared PTX3 and other markers between HD paents and healthy controls.
Methods: The study populaon included 30 paents with tunneled permanent catheter (TPC), 30 paents with
arteriovenous fistula (AVF) and 30 healthy controls. Hemogram, biochemical assays, ferrin, high sensive C-
reacve protein (hs-CRP), tumor necrosis factor-α (TNF-α) and PTX3 were evaluated in all groups.
Results: PTX levels were highest in HD paents with TPC, intermediated in HD paents with AVF and lowest in
healthy controls (5.2 + 2.4 vs. 3.1 + 1.3 vs. 1.8 + 0.7, p<0.001 for all comparisons). PTX3 levels correlated strongly to
hs-CRP (r = 0.857) and moderately to TNF-α, NLR, ferrin and total neutrophil count. PTX3 and albumin levels had
a negave correlaon. PTX3 levels were higher in paents with 8 months of TPC than those with 7 months or less.
Conclusions: PTX3 levels are significantly elevated in all paents on HD, but presence and extended duraon of
TPC are associated with incrementally higher levels of PTX3 and other inflammatory markers. PTX3 and NLR may
be useful in assessing chronic inflammatory states in HD.
Keywords: Arteriovenous fistula, Hemodialysis, Inflammaon, Pentraxin 3, Tunneled permanent catheter
Accepted: April 8, 2015
Published online: June 12, 2015
Corresponding author:
Irem Pembegul Yigit
Department of Nephrology
Malatya Government Hospital
44300 Malatya, Turkey
pembegulmd@yahoo.com